Bioequivalence Study of Simvastatin 20 mg Film Coated Tablet Manufactured by PT Kimia Farma Tbk Compared to Zocor® 20 mg Tablet Manufactured by Merck Sharp & Dohme, ltd. United Kingdom

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
Equitrust Lab - PT Kimia Farma Diagnostika
No Registry
INA-N24PRW2
Tanggal Input Registry : 02-09-2024

22-11-2022
AUC0-t , Cmax
AUC0-inf , tmax, half life
 
Bioequivalence Study of Simvastatin 20 mg Film Coated Tablet Manufactured by PT Kimia Farma Tbk Compared to Zocor® 20 mg Tablet Manufactured by Merck Sharp & Dohme, ltd. United Kingdom
Bioequivalence Study of Simvastatin 20 mg Film Coated Tablet Manufactured by PT Kimia Farma Tbk Compared to Zocor® 20 mg Tablet Manufactured by Merck Sharp & Dohme, ltd. United Kingdom
Interventional
Simvastatin 20 mg Film Coated Tablet Manufactured by PT Kimia Farma Tbk
34
 

Inclusion Criteria:

The inclusion criteria for this study include: 1) Signed informed consent; 2) Healthy based on clinical laboratory tests (routine hematology, liver function, kidney function, blood glucose, urinalysis, hepatitis B (HBsAg), hepatitis C (Anti-HCV) and HIV (Anti-HIV), medical history, and physical examination); 3) Male and female subjects (if female, consider the risks for women of childbearing age and perform pregnancy tests); 4) Age between 18-55 years; 5) Normal weight range according to Body Mass Index (BMI) 18-25 kg/m2); 6) Vital signs within the following ranges: systolic blood pressure 100- 129 mmHg, diastolic blood pressure 60-84 mmHg, normal pulse rate 60-90 bpm, oxygen saturation (SpO2) in the normal range of 95- 100%, body temperature

Exclusion Criteria:

The exclusion criteria for this study include: 1) Smoking more than 10 cigarettes per day; 2) Pregnant or breastfeeding women. Pregnancy tests will be performed during screening and prior to the administration of the investigational or comparator drug; 3) History of kidney or liver disease, or history of allergy, hypersensitivity or contraindication to the investigational bioequivalence drug (Pehadoxin Forte Tablet (Isoniazid 400 mg + Vitamin B6 10 mg)); 4) Clinically significant (routine hematology, liver function, kidney function, blood glucose, urinalysis) abnormalities; 5) Abnormal electrocardiogram (ECG); 6) Difficulty accessing veins in the left or right arm; 7) History of significant ongoing clinically or medically significant chronic or acute illness; 8) History of drug or alcohol abuse within the past 12 months (1 year) prior to screening for this study; 9) Positive serology test results for Hepatitis B (HBsAg), Hepatitis C (anti-HCV), HIV (anti-HIV). 10) History or condition that can affect drug kinetics. 11) Use of drugs or dietary supplements no more than 7 days since the start of the study. 12) Participation in previous clinical trials no more than 3 months from the start of the study. 13) Blood donation or blood loss of more than 300 ml within 3 months from the start of the study.
 
KET-954/UN2.F1/ETIK/PPM.00.02/2022 (12 Sep 2022) & S-701/UN2.F1/ETIK/PPM.00.02/2022 (24 Okt 2022)
Not applicable
Not applicable
Nungky Tri Yunica, S.T (lab.equitrust@gmail.com)